ECSP034534A - Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7 - Google Patents

Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7

Info

Publication number
ECSP034534A
ECSP034534A EC2003004534A ECSP034534A ECSP034534A EC SP034534 A ECSP034534 A EC SP034534A EC 2003004534 A EC2003004534 A EC 2003004534A EC SP034534 A ECSP034534 A EC SP034534A EC SP034534 A ECSP034534 A EC SP034534A
Authority
EC
Ecuador
Prior art keywords
heterocycloalkyl
cycloalkenyl
cycloalkyl
treatment
optionally substituted
Prior art date
Application number
EC2003004534A
Other languages
English (en)
Spanish (es)
Inventor
Patrick Bernardelli
Fabrice Vergne
Pierre Gerard Ducrot
Edwige Lorthiois
Charles Andrianjara
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ECSP034534A publication Critical patent/ECSP034534A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EC2003004534A 2000-10-02 2003-04-01 Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7 ECSP034534A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00402710A EP1193261A1 (en) 2000-10-02 2000-10-02 New thiadiazoles and their use as phosphodiesterase-7 inhibitors

Publications (1)

Publication Number Publication Date
ECSP034534A true ECSP034534A (es) 2003-07-25

Family

ID=8173891

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004534A ECSP034534A (es) 2000-10-02 2003-04-01 Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7

Country Status (44)

Country Link
US (1) US7122565B2 (pl)
EP (2) EP1193261A1 (pl)
JP (1) JP4177098B2 (pl)
KR (1) KR100614158B1 (pl)
CN (1) CN1639141A (pl)
AP (1) AP1541A (pl)
AR (1) AR035347A1 (pl)
AT (1) ATE304003T1 (pl)
AU (2) AU2001289945B2 (pl)
BG (1) BG107654A (pl)
BR (1) BR0114391A (pl)
CA (1) CA2424279A1 (pl)
CZ (1) CZ2003857A3 (pl)
DE (1) DE60113283T2 (pl)
DK (1) DK1326853T3 (pl)
DZ (1) DZ3440A1 (pl)
EA (1) EA007179B1 (pl)
EC (1) ECSP034534A (pl)
EE (1) EE200300134A (pl)
ES (1) ES2247166T3 (pl)
GE (1) GEP20053459B (pl)
GT (1) GT200100196A (pl)
HN (1) HN2001000217A (pl)
HR (1) HRP20030247A2 (pl)
HU (1) HUP0301248A3 (pl)
IL (1) IL155122A0 (pl)
IS (1) IS6759A (pl)
MA (1) MA25916A1 (pl)
MX (1) MXPA03002839A (pl)
NO (1) NO20031482D0 (pl)
NZ (1) NZ524852A (pl)
OA (1) OA12518A (pl)
PA (1) PA8529501A1 (pl)
PE (1) PE20020419A1 (pl)
PL (1) PL366332A1 (pl)
PT (1) PT1326853E (pl)
PY (1) PY0124152A (pl)
SI (1) SI1326853T1 (pl)
SK (1) SK3812003A3 (pl)
SV (1) SV2003000633A (pl)
TN (1) TNSN01139A1 (pl)
WO (1) WO2002028847A1 (pl)
YU (1) YU24503A (pl)
ZA (1) ZA200302346B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1597385A1 (en) * 2002-11-13 2005-11-23 Bayer HealthCare AG DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A1 (PDE7a1)
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するイミダゾトリアジノン誘導体
EP2433943B1 (en) 2004-07-01 2013-09-11 Daiichi Sankyo Company, Limited Intermediates for thienopyrazole derivatives having PDE7 inhibitory activity
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
WO2008119057A2 (en) * 2007-03-27 2008-10-02 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MD3995C2 (ro) * 2009-05-11 2010-07-31 Государственный Университет Молд0 Utilizare a di(µ-Ofenoxi)-di{[2-(4-aminobenzensulfamido)-5-etil-1,3,4-tiadiazol]-3,5-dibromosalicilidentiosemicarbazonato(-1)-cupru} în calitate de inhibitor al proliferării celulelor T-47D ale cancerului mamar
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
KR20130124333A (ko) 2010-11-08 2013-11-13 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
CN102276625B (zh) * 2011-08-24 2013-07-17 天津药物研究院 噻二唑衍生物
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103288777A (zh) * 2013-05-28 2013-09-11 浙江禾田化工有限公司 特丁噻草隆关键中间体2-甲基氨基-5-叔丁基-1,3,4-噻二唑的合成方法
US9416652B2 (en) 2013-08-08 2016-08-16 Vetco Gray Inc. Sensing magnetized portions of a wellhead system to monitor fatigue loading
AU2016275702A1 (en) * 2015-06-12 2017-12-21 Oryzon Genomics, S.A. Biomarkers associated with LSD1 inhibitors and uses thereof
PT3554474T (pt) 2016-12-16 2024-02-12 Baxter Healthcare Sa Composições de micafungina
CN107674042B (zh) * 2017-09-28 2020-09-25 河南科技大学 一种超声波无溶剂合成噻二唑类化合物的方法
CN113480486B (zh) * 2021-07-30 2022-05-24 赣南师范大学 一种3-胺基-1,2,4-三唑类衍生物及其制备方法和应用
AU2023326563A1 (en) 2022-08-18 2025-02-27 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE251979C (pl)
FR2388806A1 (fr) 1977-04-25 1978-11-24 Gulf Oil Corp Nouvelles 3-benzyl-2-methylimino-5-phenyl4-1,3,4 thiadiazolines et leur application au desherbage chimique de cultures
DK270880A (da) * 1979-07-09 1981-01-10 Gulf Oil Corp Phenyliminothiadiazolidiner deres fremstilling og anvendelse i plantevaekstregulerende midler
DD247003A1 (de) * 1985-11-07 1987-06-24 Hydrierwerk Rodleben Veb Verfahren zur herstellung von in 2-stellung mit amninhaltigen gruppen subst. 7 h-1,3,4-thiadiazolo(3,2-a)pyrimidinen
DD251979A1 (de) * 1986-08-01 1987-12-02 Neubauer T Paedagog Hochschule Verfahren zur herstellung von s-triazinylsubstituierten 2-imino-1,3,4-oxadiazolinen
DE4418066A1 (de) 1994-05-24 1995-11-30 Bayer Ag Substituierte Thiadiazoline
ES2203086T3 (es) * 1998-02-17 2004-04-01 Roche Diagnostics Gmbh Empleo de derivados de tiadiazolo (4,3-a)piridina.

Also Published As

Publication number Publication date
ZA200302346B (en) 2004-08-04
SV2003000633A (es) 2003-04-03
WO2002028847A1 (en) 2002-04-11
EP1326853A1 (en) 2003-07-16
HRP20030247A2 (en) 2005-04-30
PA8529501A1 (es) 2003-06-30
AU8994501A (en) 2002-04-15
CA2424279A1 (en) 2002-04-11
EA200300333A1 (ru) 2003-10-30
NO20031482L (no) 2003-04-01
ES2247166T3 (es) 2006-03-01
KR20030068542A (ko) 2003-08-21
IS6759A (is) 2003-03-27
AP2003002764A0 (en) 2003-03-31
DK1326853T3 (da) 2005-12-12
ATE304003T1 (de) 2005-09-15
SK3812003A3 (en) 2004-05-04
JP2004510769A (ja) 2004-04-08
PT1326853E (pt) 2005-11-30
SI1326853T1 (sl) 2005-12-31
BR0114391A (pt) 2003-06-24
OA12518A (en) 2006-05-29
KR100614158B1 (ko) 2006-08-21
AP1541A (en) 2006-01-11
EP1193261A1 (en) 2002-04-03
PL366332A1 (pl) 2005-01-24
US20030045557A1 (en) 2003-03-06
AR035347A1 (es) 2004-05-12
NZ524852A (en) 2004-09-24
HUP0301248A3 (en) 2005-06-28
CN1639141A (zh) 2005-07-13
TNSN01139A1 (en) 2005-11-10
MA25916A1 (fr) 2003-10-01
HN2001000217A (es) 2002-06-13
EA007179B1 (ru) 2006-08-25
US7122565B2 (en) 2006-10-17
HUP0301248A2 (hu) 2003-10-28
IL155122A0 (en) 2003-10-31
MXPA03002839A (es) 2004-09-10
JP4177098B2 (ja) 2008-11-05
BG107654A (bg) 2003-12-31
PE20020419A1 (es) 2002-07-18
GT200100196A (es) 2002-07-18
GEP20053459B (en) 2005-02-25
DE60113283D1 (de) 2005-10-13
PY0124152A (es) 2004-06-01
AU2001289945B2 (en) 2005-12-22
EP1326853B1 (en) 2005-09-07
DZ3440A1 (fr) 2002-04-11
EE200300134A (et) 2003-08-15
YU24503A (sh) 2006-03-03
NO20031482D0 (no) 2003-04-01
DE60113283T2 (de) 2006-06-08
CZ2003857A3 (cs) 2004-02-18

Similar Documents

Publication Publication Date Title
MXPA03002839A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7.
GT200100132A (es) Derivados de pirazol
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
GT200400092A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
DE60229531D1 (de) Dna-pk-inhibitoren
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
AR077267A1 (es) Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
UY26727A1 (es) Derivados de tropano útiles en terapia
WO2005092858A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
BRPI0721113A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
CL2004000965A1 (es) Compuestos derivados de 2h-pirazol-3-il de formula definida, que actuan como inhibidores de quinasa p38 y tnf; composicion farmaceutica que comprende a uno de los compuestos; uso de la composicion en la preparacion de un medicamento; y uso de los com
BRPI0417345A (pt) compostos inibidores de quìnase baseados em azola, composições e seus usos
BRPI0417007A (pt) agentes antivirais de diazaindol-dicarbonil-piperazinila
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
TW200612920A (en) Novel imidazolidine derivatives
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
MXPA03004023A (es) Compuestos quimicos.
UY26949A1 (es) Nuevos tidiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7
CR6503A (es) Derivados de- 1-trifluorometil-4-hidroxi-7-piperidinil-aminometiclcromano
CR9072A (es) 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolinocarbonitrilos para el tratamiento de lesion isquemica
PA8450901A1 (es) Derivados de eritromicina
HN2001000119A (es) S-metil-dihidro -ziprasidona para el tratamiento de trastornos psiquiatricos y oculares.
TW200508211A (en) 2-naphthylimino-1,3-thiazine derivatives
ECSP014089A (es) Derivados de tropano utiles en terapia